Rapid loss of response after withdrawal of treatment with azacitidine: A case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia

European Journal of Haematology

Volumn 90, Issue 4, 2013, Pages 345-348

  Voso, Maria Teresa ^a   Breccia, Massimo ^b   Lunghi, Monia ^c   Poloni, Antonella ^d   Niscola, Pasquale ^e   Finelli, Carlo ^f   Bari, Alessia ^g   Musto, Pellegrino ^h   Zambello, Renato ⁱ   Fianchi, Luana ^a   Alimena, Giuliana ^b   Leone, Giuseppe ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^e S EUGENIO HOSPITAL   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^h REFERRAL CANCER CENTER OF BASILICATA   (Italy)

ⁱ UNIVERSITY OF PADOVA   (Italy)

Author keywords

Azacitidine; Chronic myelomonocytic leukemia; Hypomethylating agents; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ANEMIA; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMORBIDITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HEART VENTRICLE FIBRILLATION; HIGH RISK PATIENT; HUMAN; INFECTION; INJECTION SITE REACTION; INTESTINE OBSTRUCTION; MALE; MYELODYSPLASTIC SYNDROME; NECROTIZING FASCIITIS; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 84875261536     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12079     Document Type: Article

References (16)

1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32.
2. Seymour JF, Fenaux P, Silverman LR, et al. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010;76:218-27.
3. Sanna A, Gozzini A, Gioia D, Breccia M, Cannella L, Sassolini F, Levis A, Bosi A, Alimena G, Santini V. Comorbidities influence prognosis in MDS high-risk patients treated with 5-azacitidine. Haematologica 2011;96(Suppl 2):445.
4. Vidaza Summary of Product Characteristics. Available at: http://www.medicines.org.uk/EMC/medicine/21508/SPC/Vidaza%2025%20mg%20ml%20powder%20for%20suspension%20for%20injection/. (Accessed 4 October 2012)
5. Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellstrom-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011;117:2697-702.
6. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108(2):419-25.
7. Della PM, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011;96:441-9.
8. Lubbert M, Suciu S, Baila L, et al. de WT, Wijermans PW. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011;29:1987-96.
9. Stresemann C, Bokelmann I, Mahlknecht U, Lyko F. Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther 2008;7:2998-3005.
10. Ruter B, Wijermans PW, Lubbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2′-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer 2006;106:1744-50.
11. Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011;29:3322-7.
12. Jabbour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, Kantarjian H. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010;116:3830-4.
13. Wang R, Gross CP, Maggiore RJ, Halene S, Soulos PR, Raza A, Galili N, Ma X. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes. Leuk Res 2011;35:904-8.
14. Itzykson R, Thepot S, Quesnel B, et al. de BS, Chelghoum Y, Taksin AL, Plantier I, Ame S, Boehrer S, Gardin C, Beach CL, Ades L, Fenaux P. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117:403-11.
15. Santini V, Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Silverman LR, List A. Gore S D, Seymour JF, Backstrom J, Beach CL. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol 2010;85:130-8.
16. Sekeres MA, Maciejewski JP, List AF, Steensma DP, Artz A, Swern AS, Scribner P, Huber J, Stone R. Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. Oncologist 2011;16:904-11.